Related Experiment Videos
[Human factor VIII expression in retrovirus vector-transduced bone marrow stromal cells]
1Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Second Medical University, Shanghai 200025, China.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi
|January 5, 2002
Summary
Bone marrow stromal cells (BMSCs) show promise for hemophilia A gene therapy. Optimized protocols enhanced factor VIII (FVIII) expression and secretion in transduced BMSCs, demonstrating therapeutic potential.
Area of Science:
- Regenerative Medicine
- Gene Therapy
- Hematology
Background:
- Hemophilia A is a genetic bleeding disorder caused by deficiency in factor VIII (FVIII).
- Gene therapy offers a potential curative approach for hemophilia A.
- Bone marrow stromal cells (BMSCs) are multipotent stem cells with potential for therapeutic applications.
Purpose of the Study:
- To assess the feasibility of using bone marrow stromal cells (BMSCs) for gene therapy in hemophilia A.
- To optimize the gene transfer process into BMSCs for enhanced factor VIII (FVIII) production.
Main Methods:
- Murine and rabbit BMSCs were transduced with a retroviral vector containing human FVIII cDNA.
- An optimized protocol involving temperature reduction and centrifugation was employed for transduction.
- Factor VIII expression and activity were quantified using ELISA, one-stage assays, PCR, and Western blot.
Main Results:
- Transduction efficiency was significantly increased (5- to 8-fold) with the optimized protocol.
- High levels of FVIII expression and secretion were achieved in transduced BMSCs from both mouse and rabbit.
- Secreted FVIII exhibited coagulant activity and was processed into functional heavy and light chains.
Conclusions:
- The BMSC system demonstrates significant potential for the gene therapy of hemophilia A.
- Optimized retroviral transduction of BMSCs can lead to effective FVIII production.
- This approach offers a promising strategy for developing novel hemophilia A treatments.